BIXT Stock Chart & Stats
$0.04
$0.01(17.50%)
At close: 4:00 PM EST
$0.04
$0.01(17.50%)
Day’s Range― - ―
52-Week Range$0.02 - $0.10
Previous CloseN/A
Volume481.75K
Average Volume (3M)219.43K
Market Cap
$2.46M
Enterprise Value$4.21M
Total Cash (Recent Filing)$463.05K
Total Debt (Recent Filing)$1.21M
Price to Earnings (P/E)―
Beta-1.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding98,898,384
10 Day Avg. Volume161,869
30 Day Avg. Volume219,425
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)-2.69
Price to Sales (P/S)0.00
P/FCF Ratio-13.22
Enterprise Value/Market Cap1.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-356.36
Enterprise Value/Ebitda-1.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioxytran News
BIXT FAQ
What was Bioxytran Inc’s price range in the past 12 months?
Bioxytran Inc lowest stock price was $0.02 and its highest was $0.10 in the past 12 months.
What is Bioxytran Inc’s market cap?
Bioxytran Inc’s market cap is $2.46M.
When is Bioxytran Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bioxytran Inc’s earnings last quarter?
Currently, no data Available
Is Bioxytran Inc overvalued?
According to Wall Street analysts Bioxytran Inc’s price is currently Overvalued.
Does Bioxytran Inc pay dividends?
Bioxytran Inc does not currently pay dividends.
What is Bioxytran Inc’s EPS estimate?
Bioxytran Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxytran Inc have?
Bioxytran Inc has 98,898,384 shares outstanding.
What happened to Bioxytran Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioxytran Inc?
Currently, no hedge funds are holding shares in BIXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioxytran Inc
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer. This compound is intended for tackling oxygen deprivation in the brain caused by strokes, as well as addressing wound hypoxia to avert tissue death and encourage recovery. Additionally, Bioxytran is advancing ProLectin-Rx, a pectin-derived polysaccharide. This substance functions by attaching to and inhibiting galectin-1, a specific galectin, to treat mild to moderate instances of Covid-19. Established in 2008, the company maintains its main office in Newton, Massachusetts.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---